Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved letrozole as a treatment option for the extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received prior adjuvant treatment for 5 years.

This is written in the approval document as:

Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.

Reimbursement

CDS

Citation

Letrozole Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6817/371_Letrozole_.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
HSE (1)	ER positive	Invasive Breast Carcinoma	Letrozole
HSE (1)	PR positive	Invasive Breast Carcinoma	Letrozole

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-11-11	Health Service Executive	Indication approved for reimbursement.